ReviewThe Journal of antimicrobial chemotherapy2022
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.
Review in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation versus antibiotics for treating clostridioides difficile infection: systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Microbiome-based therapeutics forGut microbes · 2026Review
- Multi-strain Clostridioides difficile infection: Increased detection and clinical implications.The Journal of infection · 2026Article
- Letter: Dose and Donor Matter-Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection.Alimentary pharmacology & therapeutics · 2026Article
- Antibiotics promote susceptibility tobioRxiv : the preprint server for biology · 2026Article
- Saccharomyces cerevisiae 48338 Suppresses Antibiotic-Induced Clostridioides difficile Infection in a Murine Model.Probiotics and antimicrobial proteins · 2026Article
- Expulsion of rope-like material per rectum in an infant: a rare case report of pseudomembranous colitis.Oxford medical case reports · 2026Article
- Current status and future perspectives of fecal immunological markers in the differential diagnosis of Clostridioides difficile infection in children.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Observational
- Pooled analyses of Clostridioides difficile vaccine trials identify baseline predictors for vaccine response.Scientific reports · 2026Article
- Oral Vancomycin in the Treatment ofAntibiotics (Basel, Switzerland) · 2026Article
- Reversion of heme-dependent metronidazole resistance inMicrobiology spectrum · 2026Article
- Patient with Inflammatory Bowel Disease in a Dental Office-Which Antibiotic to Choose?-Narrative Review.Journal of clinical medicine · 2025Review
- Epidemiology and Course of Clostridioides difficile Infections in Germany: Retrospective Analysis of German Health Claims Data.Infectious diseases and therapy · 2025Article
- Investigating the relationship between Helicobacter pylori and intestinal Clostridioides difficile infection: evidence from a cross-sectional study.BMC gastroenterology · 2025Article
- The role of Frailty Index Laboratory in predicting clinical outcomes in patients withJAC-antimicrobial resistance · 2025Article
- Comparison ofJournal of clinical medicine · 2025Article
- Risk factors and outcomes of Clostridioides difficile infection in patients with colorectal cancer: critical perspective in management.Gut pathogens · 2025Review
- Potential for Misinterpretation in the Laboratory Diagnosis ofDiagnostics (Basel, Switzerland) · 2025Article
- Fecal Microbiota Transplantation for RefractoryBlood cell therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridioides difficile infection (CDI) remains a significant clinical challenge both in the management of severe and severe-complicated disease and the prevention of recurrence. Guidelines released by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America (IDSA/SHEA) and ESCMID had some consensus as well as some discrepancies in disease severity classification and treatment recommendations. We review and compare the key clinical strategies from updated IDSA/SHEA, ESCMID and current Australasian guidelines for CDI management in adults and discuss relevant issues for clinicians, particularly in the management of severe-complicated infection. Updated IDSA/SHEA and ESCMID guidelines now reflect the increased efficacy of fidaxomicin in preventing recurrence and have both promoted fidaxomicin to first-line therapy with an initial CDI episode in both non-severe and severe disease and endorsed the role of bezlotoxumab in the prevention of recurrent infection. Vancomycin remains acceptable therapy and metronidazole is not preferred. For severe-complicated infection the IDSA/SHEA recommends high-dose oral ± rectal vancomycin and IV metronidazole, whilst in an important development, ESCMID has endorsed fidaxomicin and tigecycline as part of combination anti-CDI therapy, for the first time. The role of faecal microbiota transplantation (FMT) in second CDI recurrence is now clearer, but timing and mode of FMT in severe-complicated refractory disease still requires further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.